Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Sees Significant Growth in Short Interest

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) was the target of a significant growth in short interest during the month of January. As of January 30th, there was short interest totaling 24,900 shares, a growth of 1,055.5% from the January 15th total of 2,155 shares. Approximately 16.6% of the shares of the stock are sold short. Based on an average trading volume of 3,724 shares, the days-to-cover ratio is presently 6.7 days. Based on an average trading volume of 3,724 shares, the days-to-cover ratio is presently 6.7 days. Approximately 16.6% of the shares of the stock are sold short.

Amplify Weight Loss Drug & Treatment ETF Stock Performance

Shares of THNR traded down $0.08 during trading hours on Tuesday, hitting $26.04. 946 shares of the stock were exchanged, compared to its average volume of 4,413. The stock’s 50-day moving average price is $25.78 and its two-hundred day moving average price is $24.37. The company has a market cap of $3.91 million, a price-to-earnings ratio of 24.31 and a beta of 0.61. Amplify Weight Loss Drug & Treatment ETF has a 12-month low of $18.56 and a 12-month high of $27.28.

Amplify Weight Loss Drug & Treatment ETF Dividend Announcement

The firm also recently disclosed an annual dividend, which was paid on Wednesday, December 31st. Shareholders of record on Tuesday, December 30th were issued a $0.4132 dividend. The ex-dividend date was Tuesday, December 30th. This represents a yield of 162.0%.

Institutional Investors Weigh In On Amplify Weight Loss Drug & Treatment ETF

A hedge fund recently bought a new stake in Amplify Weight Loss Drug & Treatment ETF stock. Cravens & Co Advisors LLC acquired a new position in Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 15,023 shares of the company’s stock, valued at approximately $390,000. Cravens & Co Advisors LLC owned about 10.02% of Amplify Weight Loss Drug & Treatment ETF as of its most recent filing with the Securities and Exchange Commission.

About Amplify Weight Loss Drug & Treatment ETF

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.